Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
|Articles|May 1, 2006
Treatment admissions continue to rise for meth, Rx drugs
New data released by the Substance Abuse & Mental HealthServices Administration (SAMHSA) show admissions to substance abusetreatment involving methamphetamine and narcotic pain medicationscontinued to rise in 2004. Methamphetamine admissions to treatmentrose 11% between 2003 and 2004 and 25% between 2002 and 2004.
Advertisement
New data released by the Substance Abuse & Mental Health Services Administration (SAMHSA) show admissions to substance abuse treatment involving methamphetamine and narcotic pain medications continued to rise in 2004. Methamphetamine admissions to treatment rose 11% between 2003 and 2004 and 25% between 2002 and 2004. For opiates other than heroin, there was a 21% increase in admissions to treatment since 2003 and a 42% increase from 2002-2004. Opiates other than heroin are largely prescription pain medications.
To see more Hot off the Press news articles, click here
To go to the Drug Topics homepage, click here
Advertisement
Related to this article
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
3
Expert Discusses Flu and COVID-19 Vaccine Guidance
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5